Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 27, 2009Molecular Cancer Therapeutics

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMatthew SquiresRFRuth E. FeltellNWNicola G. Wallis

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Squires et al. (2009) studied this question.

synapsesocial.com/papers/6a8a9f31d513dfc69d721df5https://doi.org/10.1158/1535-7163.mct-08-0890
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design2008 · 342 citations
  2. 2The Proto-oncogene c-myc Acts through the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1to Facilitate the Activation of Cdk4/6 and Early G1Phase Progression2002 · 89 citations
  3. 3Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors2006 · 84 citations
  4. 4In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)2002 · 367 citations